These courses are intended for internal hospital staff.
Provide a multidisciplinary overview on the importance of early diagnosis and treatment considerations, including surgery, radiation, loco-regional approaches, and systemic therapies. Discuss the management care of oncology patients in interdisciplinary teams through the complex healthcare environment. Review new advances in therapeutic approach from oncology cases that can benefit patients.
Specialties - Surgeons, Gastroenterologists, Oncologists, Laboratory Scientists, Physician Assistants, Nurse Practitioners, Registered Nurses, Oncology Pharmacists, Radiology, Clinical Research
At the conclusion of this course, learners should be able to:
- Describe innovative options for patients with pancreas and liver cancers.
- Identify current and emerging strategies for early diagnosis and surveillance of liver cancer.
- Identify patients suitable for a liver transplantation, surgical resection, radiation therapy, or other loco-regional approaches.
- Integrate novel molecularly-targeted, as well as immune-based, therapeutic strategies in clinical care and clinical trial participation.
- Describe the latest state of the science in pancreatic and liver cancer.
Clark Kulig, MD
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.
The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.